Section 1
Do you have the organisational
processes required for best practice
in helping patients move from intensive to continuation
phase?
|
Best
Practice Requirement |
Your Current
Practice |
Identify
Gaps in your Practice |
Adequate
time is taken to reiterate important messages about
the need to continue treatment without interruption |
|
|
Patients are
encouraged to inform the health-care facility if there
are likely to be changes in personal circumstances
that may affect his or her ability to continue treatment
and/or attend for follow-up appointments |
|
|
During the continuation
phase a minimum of a monthly follow-up meeting is
agreed between the
patient and the health-care worker who supervised
the initial phase of treatment. This may involve home
or clinic visits or a mixture of both, according to
patient preference and available resources. |
|
|
Patient is reassured
that they can visit the facility at any time and that
they must feel free to report any problems should
they arise |
|
|
Principles for
sputum collection outlined in Standard 2 are applied
when
giving the patient instructions to produce subsequent
specimens at home & information on delivering
the specimen to the right place at the right time
is given |
|
|
All requested
and sent specimen dates and results of sputum smear
tests are documented to inform further treatment strategies |
|
|
Laboratory services
are efficient and there is no delay in the examination
of follow-up sputum smears. Hence treatment is changed
immediately, if required. |
|
|
Treatment card
and laboratory register are completed as outlined
in Standards 2 and 3 |
|
|
In cases where
patients do not submit the required sputum sample
no entry or an entry indicating “smear not done”
in the TB register is recorded and patient is traced
as outlined in Standard 2 |
|
|
Patients are
opportunity to discuss practicalities of starting
treatment at home |
|
|
Patients are
helped to develop a way of remembering when to take
the medicine (before a routine activity such as a
meal is useful) |
|
|
Patients are
advised regarding safe storage of the
drugs in a dark, dry place away from the reach of
children |
|
|
Any potential
barriers to adherence are reassessed, such as a change
in
routine, potential for mislaying drugs or having them
stolen, alcohol addiction and treatment plan negotiated
as appropriate with the patient |
|
|
Patients are
reminded how to recognise any potential adverse effects
and report them, as in Standard 6 |
|
|
|